Janux Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Janux Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 16% in 3 years, but profit fell: $3,643 less profit per $100 of extra sales. Lower than 98% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 91% of its market value (net cash). Higher than 87% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-54.3×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 73% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
−$3,643Sales grew 16% in 3 years, but profit fell: $3,643 less profit per $100 of extra sales.
Lower than 98% of Healthcare companies in United States.
Asset Productivity Ratio
+16% / +175%In 3 years sales changed by +16% while total assets changed by +175%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-34.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 66% of Healthcare companies in United States.
Cash Cushion Ratio
+91%Cash, after subtracting all debt, equals 91% of its market value (net cash).
Higher than 87% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Janux Therapeutics, Inc. made a loss over the last year. Janux Therapeutics, Inc. owes $0.08 for every $1 it owns. Janux Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossJanux Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.12The share price is 1.12 times Janux Therapeutics, Inc.'s book value per share, lower than 76% of Healthcare companies in United States.
Market cap
$1.0 BThe total market value of all of Janux Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 64% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$928 MWhat Janux Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$15.18Net worth divided by the number of shares. The share price of $17.06 is 1.1 times this, which is the P/B above.
Return on equity (ROE)
-10.7%Janux Therapeutics, Inc. lost 10.7% of its shareholders' money over the last year, higher than 71% of Healthcare companies in United States.
Owes vs Owns
0.08×Janux Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Dividend yield
NoneJanux Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-6%Revenue fell 6% in the year to Dec 2025, and grew 5% a year on average over 3 years.
Profit growth
LossJanux Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-1136.2%Janux Therapeutics, Inc. lost $1136 for every $100 of revenue.
Cash vs debt
Net cashJanux Therapeutics, Inc. held $944 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Janux Therapeutics, Inc.: $1.0 B ÷ $928 M (30 Jun 2026) = 1.1.
What is Janux Therapeutics, Inc.'s return on equity?
Janux Therapeutics, Inc. lost 10.7% of its shareholders' money over the last year, higher than 71% of Healthcare companies in United States.
How much does Janux Therapeutics, Inc. owe compared with what it owns?
Janux Therapeutics, Inc. owes $0.08 for every $1 it owns (low), lower than 90% of Healthcare companies in United States.
Does Janux Therapeutics, Inc. pay a dividend?
No. Janux Therapeutics, Inc. does not currently pay a dividend.
Is Janux Therapeutics, Inc.'s revenue growing?
Revenue fell 6% in the year to Dec 2025, and grew 5% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.